Ardelyx (ARDX) Q2 2026 Earnings Call Transcript
Ardelyx (ARDX) reported Q2 2026 product revenue of $118.1 million, up 31% year over year, driven by IBSRELA ($86.2 million, +33%) and XPHOZAH ($31.9 million, +27%). Net loss was $16.7 million. The company revised 2026 guidance to $350-$370 million for IBSRELA and $110-$120 million for XPHOZAH, citing payer hurdles.
How this was made
The 30-second read
Why it matters
The key trading driver is the revised IBSRELA 2026 revenue range tied to payer utilization management hurdles, alongside a strategic shift on XPHOZAH reimbursement litigation after a D.C. Circuit dismissal.
Market read
Traders can reprice near-term revenue expectations for IBSRELA based on the updated 2026 guidance and OPEX plan, while monitoring whether reimbursement support efforts stabilize new patient starts.
What to watch
Gross-to-net guidance (low to mid-30%) and the doubled reimbursement field team could offset some access friction; also, the ACCEL Phase 3 enrollment completion by end-2026 may re-rate risk later in 2026.
Background
Ardelyx reported Q2 2026 product revenue and used the earnings call to revise 2026 guidance for IBSRELA and OPEX, while addressing reimbursement litigation and clinical trial timelines.
Ticker impact
Ardelyx cut 2026 IBSRELA revenue guidance to $350M-$370M due to payer utilization management hurdles and slower new patient starts.
Bias to downside or higher volatility until investors digest payer-access headwinds and the updated gross-to-net and OPEX plan.
The article discloses specific, time-bound guidance changes (IBSRELA and OPEX), plus a reimbursement litigation withdrawal tied to a court ruling, which can directly affect expectations for net sales and access.
Market effects
Reinforces that GI reimbursement access and prior authorization step edits can materially pressure net sales trajectories for oral phosphate-lowering therapies.
Limited, primarily US payer and CMS reimbursement dynamics.
Low, as the disclosed drivers are US reimbursement and a US court decision.
Counterpoint
The company’s record product revenue and reiterated XPHOZAH guidance suggest payer hurdles may be more manageable than the magnitude of the IBSRELA cut implies.
Key entities
- companyArdelyx, Inc.
Subject of the earnings call transcript, providing Q2 results, revised 2026 guidance, and updates on reimbursement and clinical timelines.
- regulatorCenters for Medicare & Medicaid Services (CMS)
Ardelyx previously sued CMS over XPHOZAH reimbursement; the D.C. Circuit affirmed dismissal, ending that litigation pursuit.
- financing counterpartSLR Investment Corp.
Source of a $50M drawdown from the SLR financing arrangement during the quarter.
